Novel 2'(β)-methyl-5'-deoxyapiose purine phosphonic acid analogues were designed and synthesized from 2-propanone-1,3-diacetate. Condensation successfully proceeded from a glycosyl donor 9 under Vorbrüggen conditions. Condensation of aldehyde 14 with Wittig reagent [(diethoxyphosphinyl)methylidene] triphenylphosphorane gave the desired nucleoside phosphonate analogues 15. Ammonolysis and hydrolysis of phosphonates gave the nucleoside phosphonic acid analogue 17 and 19. The synthesized nucleoside analogues were subjected to antiviral screening against HIV-1. The adenine analogue 19 exhibited weak in vitro activities against HIV-1.
Introduction
Nonclassical nucleosides continue to be a promising challenge for the development of new antiviral agents since the discovery of lamivudine as anti-human immunodeficiency virus (HIV) and anti-hepatitis B virus (HBV) agent [1] . The apio dideoxynucleoside also belong to the class of nonclassical nucleoside in that 4-hydroxymethyl of the 2.3-dideoxyribose moves to the C3 position. This class of nucleosides like (1) ( Figure  1) showed not only the antiviral activity, but also metabolic advantage such as resistance to adenosine deaminase and glycosyl bond hydrolysis, when compared to the classical 2,3-dideoxynucleosides [2] . Apiose 5'-nornucleoside phosphonates [3] , such as, PMDTA (2) and PMDTT (3), have been assembled from natural precursor molecules. Furthermore, it has been demonstrated apiose nucleic acids (TNA) form thermal stable duplexes with DNA and RNA that are reminiscent of the natural associations of nucleic acids [4] . Moreover, diphosphates of apiose nucleosides are accepted as substrates by several polymerases, and can be enzymatically incorporated into DNA [5] . In addition, these nucleosides are also accepted as substitutes for ribonucleosides at the catalytic site of hammerhead ribozyme, although the catalytic efficiency of ribozyme is then significantly reduced [6] . PMDTA has a phosphonomethoxy group at the 3'-position of its furanose ring and no substituent at the 4'-position. This absence of a 4'-hydroxymethyl group avoids problems of steric hindrance during phosphorylation reactions with kinases.
Recently, 2'(β)-azido-apiose 5'-nornucleoside phosphonic acid (4) was synthesized from 2,3-dihydroxydihydrofuran-1-one [7] . To study the influences of
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different substituents on anti-HIV activity further, we undertook to synthesize 2'(β)-fluorinated analogues of PMDTA. Stimulated by the findings that apiosyl nucleoside analogues and 5'-nornucleoside phosphonic acids have excellent antiviral activities, we sought to synthesize a novel class of nucleosides consisting of 2'(β)-methylapiose nucleoside and its 5'-deoxyphosphonic acid analogues to find therapeutics that are more effective against HIV.
Experimental Section
Uncorrected melting points were determined on a Mel-temp II laboratory device. NMR spectra were recorded on a JEOL 300 Fourier transform spectrometer (JEOL, Tokyo, Japan); chemical shifts are reported in parts per million (δ) and signals are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), or dd (doublet of doublets). UV spectra were obtained on a Beckman DU-7 spectrophotometer (Beckman, South Pasadena, CA, USA). MS spectra were collected in electrospray ionization (ESI) mode. Elemental analyses were performed using a Perkin-Elmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA). TLC was performed on Uniplates (silica gel) purchased from Analtech Co. (7558, Newark, DE, USA). All reactions were carried out in a nitrogen atmosphere unless otherwise specified. Dry dichloromethane, benzene, and pyridine were obtained by distillation from CaH 2 . Dry THF was obtained by distillation from Na and benzophenone immediately prior to use.
3-Methyl-4-(t-butyldimethylsilyloxymethyl)furan-2(5H)-one (7): TBDMSCl (2.25 g, 14.99 mmol) was added slowly at 0 o C to a solution of 6 (1.74 g, 13.63 mmol) and imidazole (1.86 g, 27.26 mmol) in CH 2 Cl 2 (60 mL), and stirred for 4 h at room temperature. The solvent was evaporated under a reduced pressure. The residue was diluted with H 2 O (100 mL) and extracted twice with EtOAc (100 mL x2). The combined organic layer was dried over anhydrous MgSO 4 , filtered, and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/ hexane, 1:8) to give compound 7 (2.77 g, 84%): 
To a solution of lactone 7 (4.92 g, 20 mmol) in 100 mL of EtOAc was added 1.0 g of Pd/C (5% w/w) under H 2 atmosphere, and the mixture was stirred for 6 h. After filtration of the reaction mixture through a celite pad, the filtrate was concentrated and purified by silica gel column chromatography (EtOAc/hexane, 1:15) to give compound 8 (4.46 g, 88%). The reaction was quenched with 3 mL of MeOH and warmed to room temperature for 1 h and aq NaHCO 3 (5 mL) and EtOAc (60 mL) were added to the mixture. The resulting mixture was filtered, and the filtrate was concentrated to dryness. A solution of the crude lactol in CH 2 Cl 2 (60 mL) was treated with Ac 2 O (1.48 mL, 15.84 mmol), TEA (2.2 mL, 15.84 mmol) and a catalytic amount of 4-DMAP (15 mg) at room temperature for 6 h. The resulting mixture was concentrated and purified by silica gel column chromatography (EtOAc/hexane, 1:20) to give compound 9 (1.03 g, 68%). (rel)-(1'S,2'S,3'R)-9-(3'-t-Butyldimethylsilanyloxymethyl-2'-methyl-tetrahydrofuran-1'-yl) 6-chloropurine (10α) and (rel)-(1'R,2'S,3'R)-9-(3'-t-butyldimethylsilanyloxymethyl-2'-methyl-tetrahydrofuran-1'-yl) 6-chloropurine (10β): 6-Chloropurine (235 mg, 1.52 mmol), anhydrous HMDS (12 mL), and a catalytic amount of ammonium sulfate (15.2 mg) were refluxed to a clear solution, and the solvent was then distilled off under anhydrous conditions. The residue obtained was dissolved in anhydrous 1,2-dichloroethane (12 mL), and to this mixture, a solution of 9 (290 mg, 0.76 mmol) in dry DCE (12 mL) and TMSOTf (338 mg, 1.52 mmol) was added, and stirred for 6 h at rt. The reaction mixture was quenched with 10.0 mL of saturated NaHCO 3 , stirred for 2 h, filtered through a Celite pad, and the filtrate obtained was then extracted twice with CH 2 Cl 2 (100 mL). Combined organic layers were dried over anhydrous MgSO 4 , filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (EtOAc/hexane/3:1) to give compounds 10α (101 mg, 35%) and 10β (96 mg, 33%). Data for 10α: (13): Compound 13 was synthesized from 10β by the similar procedure described for 12: yield 90%; (rel)-(1'R,2'S,3'R)-9-(3'-Carbaldehyde-2'-methyltetrahydrofuran-1'-yl) 6-chloropurine (14) : To a mixture of CrO 3 (1.58 g, 15.93 mmol) in CH 2 Cl 2 (25 mL) and DMF (6 mL) was added pyridine (2.61 mL, 32.4 mmol) and stirred for 20 min at rt. To the mixture, nucleoside analogue 13 (1.05 g, 3.97 mmol) was added as a solution in CH 2 Cl 2 (12 mL) and DMF (3.0 mL), followed by addition Ac 2 O (1.62 g, 15.93 mmol) and stirred for 10 min at rt. The reaction was quenched by addition of ethanol (4.32 mL), further diluted with ethyl acetate (250 mL). The resulting mixture was filtered through a silica gel column topped with a layer of anhydrous Na 2 SO 4 , and filtrate was concentrated in vacuo to give the crude aldehyde 14. The crude product was subjected to next reaction without further purification.
(rel)-(1'R,2'S,3'S)-Diethyl {9-(3'-vinyl-2'-fluoro-tetrahydrofuran-1'-yl) 6-chloropurine} phosphonate (15): Immediately, after its preparation, a solution of the unpurified previous aldehyde 14 in anhydrous DMSO (28 mL) was treated with Wittig reagent (1.22 g, 3.97 mmol) and the resulting solution was stirred for 20 hr at rt. After the reaction was diluted with distilled water (28 mL) and stirred for 1 h, the mixture was extracted with CH 2 Cl 2 (200 mL) three times. The combined extract was washed with water and then saturated brine. The organic layer was dried over anhydrous Na 2 SO 4 , concentrated in vacuo, and the residue was purified by column chromatography using a gradient solvent system ( 
Anti-HIV assay
Flat bottom, 96-well plastic microtiter trays were filled with 100 µL of complete medium using a Titertek Multidrop dispenser. This eight-channel dispenser could fill a microtiter tray in less than 10 s. subsequently, stock solutions (10 x final test concentration) of compounds were added in 25-µL volumes to two series of triplicate wells so as to allow simultaneous evaluation of their effects on HIV-and mock-infected cells. Serial five-fold dilutions were made directly in the microtiter trays using an eight-channel Titertek R pipette. Untreated control HIV-and mock-infected cell samples were included for each compound. Exponentially growing MT-4 cells were centrifuged for 10 min at 140 × g and the supernatants were discarded. The pellet was either infected with 100 CCID 50 or mock-infected. The MT-4 cells were resuspended at 4×10
5 cells/mL in two flasks which were connected with an autoclavable dispensing cassette of a Titertek R Mul-tidrop dispenser. Under slight magnetic stirring 100-µL volumes were then transferred to the microtiter tray wells. The outer row wells were filled with 100 µL of medium. The cell cultures were incubated at 37 o C in a humidified atmosphere of 5% CO 2 in air. The cells remained in contact with the test compounds during the whole incubation period. Five days after infection the viability of mockand HIV-infected cells was examined either microscopically in a hemacytometer by the trypan blue exclusion method or spectrophotometrically by the MTT method.
MTT Assay
The MTT assay is based on the reduction of the yellow coloured 3-(4,5-dime-thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) by mitochondrial dehydrogenases of metabolically active cells to a blue formasan which can be measured spectrophotometrically. Therefore, to each well of the microtiter trays 20 µL of a solution of MTT (7.5 mg/mL) in phosphatebuffered saline was added using the Titertek R Multidrop. The trays were further incubated at 37 o C in a CO 2 incubator for the indicated times. A fixed volume of medium (150 µL) was then removed from each cup using an eight-channel pipette without disturbing the MT-4 cell clusters containing the formazan crystals. If necessary, this step was preceded by centrifugation of the microtiter trays (450×g, 5 min) in a plate holder (8 trays per run). Solubilization of the formazan crystals was achieved by adding 100 µL 10% (v/v) Triton X-100 in acidified isopropanol (2 mL concentrated HCl per 500 mL solvent) using the Titertek R Multidrop. Complete dissolution of the formazan crystals could be obtained after the trays had been placed on a plate snaker for 10 min. Finally, the absorbances were read in an eight-channel computer-controlled photometer (Multiskan MCC, Flow Laboratories) at two wavelengths (540 and 690 nm). The absorbance measured at 690 nm was automatically subtracted from the absorbance at 540 nm, so as to eliminate the effects of nonspecific absorption. Blanking was carried out directly on the microtiter trays with the first column wells which contained all reagents except for the MT-4 cells. All data (CD 50 ) was defined as the concentration of compound that reduced the absorbance (OD 540 ) of the mock-infected control sample by 50%. The percent protection achieved by the compounds in HIV-infected cells was calculated by the following formula: expressed in % whereby (OD T ) HIV is the optical density measured with a given concentration of the test compound in HIVinfected cells; (OD C ) mock is the optical density measured for the control untreated mock-infected cells; all OD values determined at 540 nm. The dose achieving 50% protection according to the above formula was defined as the 50% effective dose (ED 50 ).
Results and Discussion
As depicted in Scheme 1, target compounds were prepared from the 2-methylbutenolide 6, which was readily prepared from 2-propanone-1,3-diacetate 5, as previously described [8] . 2-Methylbutenolide 7 was hydrogenated to 2-methyllactone 8 by treatment with 5% Pd/C under H 2 in a 90% yield. DIBAL reduction of the 2- methyllactone 8 followed by acetylation using Ac 2 O and triethylamine in CH 2 Cl 2 gave the key intermediate 9 (Scheme 1). The synthesis of adenine nucleoside was carried out by Vorbrüggen condensation [9] of compound 9 with silylated 6-chloropurine using TMSOTf as a catalyst in DCE to give the protected 6-chloropurine derivatives 10a and 10b, respectively. A complete NOE study allowed the unambiguous determinations of their relative stereochemistries (Figure 2 ). For compound 10b, strong NOE (1.5%) of H-1′↔CH-3′, which showed a 1′,3′-cis relationship, was observed. According to this result, the 3′-hydroxymethyl group and the 1′-purine base of 10b were located on the β face. On the other hand, for 10a compound, weak NOE (0.7%) of H-1′↔CH-3′, demonstrating a 1′,3′-trans relationship. Transformation of chlorine group of the purine to amine and sequential desilyaltion of corresponding nucleoside gave apiosyl adenine nucleoside 12 (Scheme 2).
Moffat oxidation [10] of the alcohol of 13 gave the aldehyde 14, which was subjected to Wittig condensation [11] using [(diethoxyphosphinyl)methylidene] triphenylphosphorane to give phosphonate nucleoside analogue 15 at a yield of 58%. The chlorine group of the purine phosphonate analogue 15 was then converted to amine with methanolic ammonia at 63 o C to give the corresponding adenosine phosphonate derivative 16 at a yield of 59%. Hydrolysis of the diethyl phosphonate functional groups of 16 by treatment with bromotrimethylsilane in CH 3 CN in the presence of 2,6-lutidine then gave the adenosine phosphonic acid derivative 17 [12] . When the vinylidene phosphonate 16 was saturated under transfer catalytic hydrogenation conditions [13] , it produced the ethyl phosphonate nucleoside analogue 18 at a yield of 67%. The adenosine phosphonic acid analogue 19 was prepared using conditions similar to the ammonolysis and hydrolysis described to produce 17 (Scheme 3).
Anti-HIV Activity A rapid, sensitive and automated assay procedure was developed for the in vitro evaluation of anti-HIV agents [14] . The synthesized nucleoside, its phosphonic acids 12, 17 and 19 were then evaluated for antiviral activity against human immunodeficiency virus [15] . As shown in Table 1 , adenine nucleoside phosphonic acid 19 exhibits weak anti-HIV activity. However, nucleoside analogues 12 and 17 did not show anti-HIV activity or cytotoxicity at concentrations up to 100 µM.
Conclusion
Based on the potent anti-HIV activity of 5′-norapiosenucleoside phosphonic acid analogues, we have designed and successfully synthesized novel 5′-norcarbocyclic nucleoside analogues starting from 2-propanone-1,3-diacetate 5. Although the adenine 5′-norapiose nucleoside phosphonic acid analogue 2 inhibits in vitro anti-HIV activity comparable to that of PMEA, the synthesized 2′-branched-5′-deoxyversions did not show anti-HIV activity. Only adenine analogue 19 showed weak anti-HIV activity. Since apiofurans are not perfect mimics for ribofuranose moiety, the mechanisms of virus inhibition, that is, either phosphorylation or inhibition of RNA synthesis, might be impaired in these compounds. Methylation of 2′-position is another possible reason for the apparent lack of activity. Figure 3 shows the superposition of the calculated low energy conformers of 2 and 19, highlighting closer position parts such as phosphonic acid parts and purine bases moieties [16] . (2) and 19.
